Proteinuria Therapeutics

Proteinuria Therapeutics

Global Proteinuria Therapeutics Market to Reach US$2.6 Billion by 2030

The global market for Proteinuria Therapeutics estimated at US$1.8 Billion in the year 2023, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. Angiotensin-converting Enzyme (ACE) Inhibitors, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$949.2 Million by the end of the analysis period. Growth in the Angiotensin Receptor Blockers (arbs) segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$502.2 Million While China is Forecast to Grow at 9.0% CAGR

The Proteinuria Therapeutics market in the U.S. is estimated at US$502.2 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$566.9 Million by the year 2030 trailing a CAGR of 9.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Proteinuria Therapeutics Market - Key Trends and Drivers Summarized

What Is Proteinuria and Why Is Its Treatment So Critical?

Proteinuria, characterized by the presence of abnormal amounts of protein in the urine, is a key indicator of kidney damage and often serves as a warning sign for chronic kidney disease (CKD). The condition arises when the kidneys` filtering units, known as glomeruli, are damaged and cannot retain proteins in the bloodstream, leading to their leakage into the urine. Untreated proteinuria can accelerate the progression of kidney disease, leading to further renal dysfunction and potentially necessitating dialysis or kidney transplantation. Proteinuria is not only a marker of kidney disease but also a risk factor for cardiovascular events, making its management crucial for preventing complications that can significantly impact a patient`s quality of life. Treatment typically focuses on controlling underlying conditions such as diabetes and hypertension, using therapies that reduce protein leakage and slow kidney damage progression.

Who Needs Proteinuria Therapeutics and Why Are They So Essential?

Proteinuria therapeutics are particularly vital for patients diagnosed with chronic kidney disease, diabetes, hypertension, and glomerulonephritis—conditions that often lead to or exacerbate proteinuria. These therapies are essential because they address the underlying mechanisms that cause protein leakage, thereby protecting kidney function and reducing the risk of severe complications. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are commonly prescribed to manage proteinuria, as they help lower blood pressure and reduce protein excretion. Additionally, newer classes of drugs, such as sodium-glucose co-transporter-2 (SGLT2) inhibitors, have shown promise in not only reducing proteinuria but also providing cardiovascular benefits, making them an important addition to the therapeutic arsenal. The goal of proteinuria treatment is not only to manage symptoms but to delay or prevent the progression of kidney disease, making these therapies a cornerstone of renal care.

What Are the Latest Trends and Innovations in Proteinuria Therapeutics?

The field of proteinuria therapeutics has witnessed significant advancements, with ongoing research focused on developing more effective and targeted treatments. One of the most notable trends is the exploration of novel drug classes, such as endothelin receptor antagonists and mineralocorticoid receptor antagonists, which offer new mechanisms of action for reducing proteinuria and protecting kidney function. Additionally, there is growing interest in combination therapies that integrate traditional ACE inhibitors or ARBs with newer agents like SGLT2 inhibitors or finerenone, aiming to provide comprehensive management of proteinuria and its associated risks. Precision medicine is also making inroads in this field, with therapies being tailored based on genetic and biomarker profiles to enhance treatment efficacy and minimize adverse effects. Furthermore, advances in non-invasive monitoring technologies are enabling more accurate assessment of proteinuria levels, allowing for better disease management and timely therapeutic adjustments. These innovations are driving the evolution of proteinuria therapeutics, offering hope for improved outcomes for patients with kidney disease.

What Is Driving the Growth of the Proteinuria Therapeutics Market?

The growth in the proteinuria therapeutics market is driven by several factors that reflect the increasing prevalence of chronic kidney disease and related conditions globally. A primary driver is the rising incidence of diabetes and hypertension, which are major contributors to the development of proteinuria. As these conditions become more widespread, particularly in aging populations and emerging markets, the demand for effective proteinuria therapies is expected to rise. Technological advancements in drug development, particularly the introduction of novel therapeutic classes and combination therapies, are also propelling market growth by offering more effective treatment options. The increasing focus on early diagnosis and management of kidney disease is further accelerating the adoption of proteinuria therapeutics, as healthcare providers seek to prevent the progression of kidney damage. Additionally, the growing awareness of the link between proteinuria and cardiovascular risk is driving demand for treatments that offer dual benefits in managing both renal and cardiovascular health. These factors, coupled with ongoing research and development efforts, are fueling the expansion of the proteinuria therapeutics market.

Select Competitors (Total 49 Featured) -

• Alnylam Pharmaceuticals, Inc.
• Apellis Pharmaceuticals
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Calliditas Therapeutics AB
• Certa Therapeutics
• Everest Medicines
• Ionis Pharmaceuticals, Inc.
• Ligand Pharmaceuticals, Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Travere Therapeutics
• Vertex Pharmaceuticals Inc.
• Walden Biosciences, Inc.
• ZyVersa Therapeutics, Inc.;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.